Epidermal growth factor (EGF) vs GHK-Cu
How Epidermal growth factor (EGF) and GHK-Cu compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Epidermal growth factor (EGF) and GHK-Cu come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Epidermal growth factor (EGF) vs GHK-Cu, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Epidermal growth factor (EGF) | GHK-Cu |
|---|---|---|
| What it is | Endogenous 53-amino-acid growth factor and recombinant cosmetic or wound-healing ingredient | Naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine complexed with copper(II)) |
| Class / category | Cosmetic / skin | Cosmetic / skin |
| Evidence tier | Human (controlled) · Mixed | Human observational · Mixed |
| Studied / approved for | Diabetic foot ulcer healing; Burn wound healing; Post-procedure skin recovery; Facial wrinkles and photoaging | Skin aging and wrinkles; Skin wound healing; Anti-inflammatory / anti-fibrosis |
| US regulatory status (2026) | unscheduled (as of Jul 2026) | research use only (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 1 |
| Banned in sport (WADA) | Unknown | Yes — on the WADA prohibited list |
| Key risks | Small topical studies report generally good short-term tolerability, with brief redness or prickling when micro-spicules disrupt the barrier. Long-term cosmetic safety has not been established. EGF deliberately activates a cell-growth pathway, which creates a theoretical tumor-promotion concern, but the available topical trials do not show that EGF serum causes cancer. | GHK-Cu has a long track record as a topical cosmetic ingredient with few reported problems beyond occasional irritation. Injected or systemic use is far less studied in humans. FDA flags compounded injectable GHK-Cu for potential immunogenicity from aggregation and peptide-related impurities and says human safety data are limited. There is no long-term human safety dataset for injected GHK-Cu. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Epidermal growth factor (EGF) vs GHK-Cu: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want the option with more human evidence behind it
Leans toward Epidermal growth factor (EGF)
Epidermal growth factor (EGF)'s evidence sits at human (controlled), a more human tier than GHK-Cu's human observational. That reflects how the data was gathered, not a guarantee it works.
References
- 1.Human epidermal growth factor — PubChem CID 16143379
- 2.Human pro-epidermal growth factor — UniProt P01133
- 3.Ha et al., 2017 — micro-spicule EGF for periocular wrinkles
- 4.Tsang et al., 2003 — human EGF for diabetic foot ulcers (PMID 12766123)
- 5.Wang et al., 2002 — rhEGF ointment for burn wounds (PMID 12569689)
- 6.Techapichetvanich et al., 2018 — rhEGF after fractional laser (PMID 29956440)